Small molecule · Inhibitor of WEE1 tyrosine kinase (WEE1) · developed by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
Azenosertib is an oral small-molecule inhibitor of the WEE1 tyrosine kinase, which normally phosphorylates CDK1 in the CDK1/cyclin B complex to block entry into mitosis. By inhibiting WEE1, it removes the G2 checkpoint, promoting premature mitosis and cell death in susceptible tumor cells, particularly p53-deficient or mutated cancers treated with DNA-damaging agents. It is being studied in pancreatic ductal adenocarcinoma, ovarian cancer, and acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07546500 | Phase 3 | Ovarian Cancer | Recruiting | ZNTL |
| NCT06015659 | Phase 2 | Advanced Pancreatic Adenocarcinoma | Terminated | ZNTL |
| NCT05682170 | Phase 1/2 | Acute Myeloid Leukemia (AML) | Terminated | ZNTL |
| NCT04005690 | Early Phase 1 | Locally Advanced Pancreatic Ductal Adenocarcinoma | Recruiting | CRDF |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaOvarian CancerResectable Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal AdenocarcinomaAcute Myeloid Leukemia (AML)Advanced Pancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the ZNTL page.
See ZNTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZNTL catalysts and pipeline →